Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 7 - Stockholders' Equity (Details Textual)

Note 7 - Stockholders' Equity (Details Textual)							3 Months Ended			6 Months Ended
Note 7 - Stockholders' Equity (Details Textual)	Jun. 24, 2024 shares	May 10, 2024 USD ($) $ / shares	May 01, 2024 USD ($)	Apr. 25, 2024 shares	Jan. 05, 2024 USD ($) $ / shares shares	Feb. 03, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Mar. 31, 2024 $ / shares shares	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) shares	May 31, 2024 $ / shares shares	Apr. 28, 2024 $ / shares shares	Jan. 31, 2024 $ / shares shares	Jan. 09, 2024 $ / shares shares	Dec. 31, 2023 $ / shares shares	Nov. 30, 2023 $ / shares shares	Jan. 31, 2023 $ / shares shares	Jan. 30, 2023 shares	Sep. 22, 2022	Dec. 31, 2021 shares	Sep. 13, 2019 $ / shares	Sep. 13, 2016 shares
Preferred Stock, Shares Authorized (in shares)							2,000,000			2,000,000						2,000,000							2,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 0.0001			$ 0.0001						$ 0.0001
Common Stock, Shares Authorized (in shares)							200,000,000			200,000,000					200,000,000	75,000,000
Stockholders' Equity Note, Stock Split, Conversion Ratio										75
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares							$ 8.64	$ 29.5		$ 8.64						$ 32.42
Fair Value Adjustment of Warrants \| $							$ (255,000)		$ 150,000	$ (139,000)	$ 1,028,000
Proceeds from Warrant Exercises \| $										$ 9,421,000	0
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares		$ 0.0001					$ 0.0001			$ 0.0001					$ 0.0001	$ 0.0001
Proceeds from Issuance of Common Stock \| $										$ 295,000	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)								283,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)										0
Invagen Pharmaceuticals Inc [Member]
Contingent Fee, Percentage of Proceeds of Future Financings						7.50%
Contingent Fee, Maximum Allowable Amount \| $						$ 4,000,000
Payment of Contingent Fee \| $										$ 600,000
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount \| $							$ 100,000			$ 100,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										1 year 3 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)										45
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										1 year 6 months
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount \| $							$ 600,000			$ 600,000
Two Thousand Fifteen Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	5,070,223																				3,556
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)							5,044,701			5,044,701
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Two Thousand Fifteen Incentive Plan [Member] \| Maximum [Member] \| Incentive Stock Options [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	5,000,000
Two Thousand Fifteen Incentive Plan [Member] \| Maximum [Member] \| Share-Based Payment Arrangement, Nonemployee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)																			70,223
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)	500,000
January 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																		25,871
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares					$ 22.545													$ 116.25
Fair Value Adjustment of Warrants \| $					$ 100,000
November 2023 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													221,333				194,667
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares					$ 22.545								$ 22.545				$ 22.545
New Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					220,538
Warrants and Rights Outstanding, Term (Year)					5 years
Warrants and Rights Issued Classified as Deemed Dividend \| $					$ 600,000
New Series B Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					220,538
Warrants and Rights Issued Classified as Deemed Dividend \| $					$ 4,300,000
Existing Warrants [Member]
Proceeds from Warrant Exercises \| $					$ 4,500,000
October 2022 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													27,271
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares													$ 116.25
Fair Value Adjustment of Warrants \| $			$ (100,000)
January 2024 Warrant Inducement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													441,076	25,871
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares													$ 22.545	$ 22.545
May 2024 Warrant Inducement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												689,680
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares												$ 6.2	6.2
Fair Value Adjustment of Warrants \| $			200,000
Warrants and Rights Issued Classified as Deemed Dividend \| $			4,500,000
Proceeds from Warrant Exercises \| $			$ 3,700,000
Warrant Payment, Price Per Share (in dollars per share) \| $ / shares													$ 0.125
New Class C Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													689,680
New Class D Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)													689,680
Shelf [Member]
Securities, Remaining Available for Sale, Amount \| $							$ 24,600,000			$ 24,600,000
ATM Agreement [Member]
Offering Agreement, Maximum Amount \| $		$ 3,850,000
Commission Fee, Percent Fee		3.00%
Stock Issued During Period, Shares, New Issues (in shares)							87,683
Proceeds from Issuance of Common Stock \| $							$ 300,000
Common Stock [Member]
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)				86,518			86,518			86,542
Stock Issued During Period, Shares, New Issues (in shares)							25,567			53,586	4,997
Common Stock [Member] \| ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)							84,683			84,683
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				75			75
Preferred Class A [Member]
Preferred Stock, Shares Authorized (in shares)																							250,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares																						$ 0.0001
Preferred Stock, Convertible, Conversion Ratio																				1,125